Sivaprakash Ramalingam

This paper develops viroVbot, an in vivo CAR-T platform with reduced immunogenicity and safety, showing efficacy in treating multiple myeloma and gastric cancer through sequential redosing.

This paper develops SHEDLOCK CAR-T cells that block BCMA shedding, enhancing their cytotoxicity and longevity in multiple myeloma models.

This study identifies SphK1 as a druggable target in human macrophages for anti-leishmanial therapy by showing its role in promoting Leishmania donovani survival through immune evasion and cell fate regulation.

This study designs and evaluates AI-optimized CAR-T cells with AKT3 degradation to improve persistence and overcome antigen escape in cancer therapy.

This study shows that host PMCA4b variations affect intraerythrocytic calcium and ROS levels, reducing artemisinin sensitivity in malaria parasites.

This study shows that KAT3 mutations impair neural crest migration via EMT regulators snai1b and snai2 in Rubinstein Taybi Syndrome, using zebrafish models and human iPSC-derived cells.

This paper introduces SNAPseq, a high-throughput NGS method for detecting β-thalassemia and sickle cell disease with 100% sensitivity and specificity using noninvasive samples.

This study corrects GBA mutations in hiPSCs to restore macrophage function in Gaucher disease and shows increased susceptibility to Mycobacterium tuberculosis.

This paper demonstrates that Francisella novicida Cas9 (FnCas9) has high specificity and low off-target editing, enabling precise genome editing in mammalian cells.